What is it about?
Phosphatidylserine (PS) is an immunosuppressive lipid. Antibodies that target PS can reduce PS-mediated immune suppression and facilitate an anti-tumor immune response. The key experiments in understanding the function of PS targeting antibodies are described and examples of immune modulation in tumor-bearing animals after treatment with PS targeting antibodies are discussed.
Featured Image
Why is it important?
Immune oncology strategies to treat cancer are changing how cancer patients are treated today. However, a significant fraction of cancer patients do not respond to current therapies. Identification of avenues to enhance the activity of current and future immune focused anti-cancer strategies has the potential to significantly improve patient outcome.
Perspectives
This review is distinct among articles focused on PS targeting because it provides a historical overview of how PS targeting agents, which were initially thought to be anti-vascular agents, were recognized as having an impact on tumor immune suppression.
rolf brekken
UT Southwestern
Read the Original
This page is a summary of: Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer, ImmunoTargets and Therapy, January 2018, Dove Medical Press,
DOI: 10.2147/itt.s134834.
You can read the full text:
Contributors
The following have contributed to this page
